secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001725160-25-000119
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports azenosertib triplet achieves 35% ORR and 5.8-month PFS in BRAFi-naïve mCRC at ASCO 2025
--------------------------------------------------------------------------------

- ORR of 35.3% (12/34 confirmed responses) in BRAF inhibitor-naïve patients; median DoR 6.0 months (95% CI 4.4-NE).
- Median PFS of 5.8 months (95% CI 3.9-9.2) in BRAF-naïve subset; prior BRAFi-treated patients had 1.8 months.
- MTD set at azenosertib 300 mg + encorafenib 75 mg + cetuximab 500 mg/m2; no DLTs at MTD, manageable safety.
- Most common TRAEs were asthenia (36%) and decreased appetite (34%); grade 3/4 asthenia occurred in 11% across all doses.
- Efficacy exceeded historical encorafenib + cetuximab doublet (BEACON: ORR 20%, PFS 4.2 months) in BRAF-naïve mCRC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/0001725160-25-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516025000119/zntl-20250531.htm
  HTML page:      https://secwatch.observer/filing/0001725160-25-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer